Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure

Detalles Bibliográficos
Autores principales: Masotti, Luca, Cioni, Elisa, Grifoni, Elisa, Cei, Francesco, Tarquini, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167827/
https://www.ncbi.nlm.nih.gov/pubmed/35680497
http://dx.doi.org/10.1016/j.ejim.2022.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167827/
https://www.ncbi.nlm.nih.gov/pubmed/35680497
http://dx.doi.org/10.1016/j.ejim.2022.06.004

Ejemplares similares